| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 50,667 | $0.36 | $18,234.36 | - | - | - | |
| Nov 11, 2021 | PFE Pfizer Inc | Young John D | Group President | Sell | 150,000 | $50.06 | $7,508,732.08 | -3.2% | +3.4% | -2.1% | |
| Nov 11, 2021 | PFE Pfizer Inc | Dolsten Mikael56 | President R&D | Sell | 59,664 | $50.29 | $3,000,646.92 | -2.6% | +3.4% | -2.1% | |
| Nov 11, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 7,813 | $21.67 | $169,307.71 | -8.6% | +23.1% | +33.7% | |
| Nov 11, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 10,000 | $21.33 | $213,300.00 | -8.6% | +23.1% | +33.7% | |
| Nov 10, 2021 | LQDA Liquidia Corp | Schundler Russell58 | General Counsel | Buy | 117,908 | $4.21 | $496,834.09 | +30.7% | +56.3% | +15.6% | |
| Nov 10, 2021 | ZTS Zoetis Inc. | Knupp Catherine A. | Executive Vice President | Sell | 10,000 | $217.19 | $2,171,900.00 | -18.6% | -6.9% | -33.7% | |
| Nov 10, 2021 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 13,333 | $30.12 | $401,645.96 | -1.9% | -8.9% | +98.0% | |
| Nov 10, 2021 | LQDA Liquidia Corp | Kirsch Arthur S | Director | Buy | 30,000 | $4.24 | $127,200.00 | +1,500% | +56.3% | +15.6% | |
| Nov 10, 2021 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairman &CEO | Sell | 3,083 | $200.00 | $616,600.00 | -96.0% | -1.4% | +30.1% | |
| Nov 9, 2021 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 9,446 | $220.00 | $2,078,120.00 | -28.2% | -8.9% | -39.1% | |
| Nov 9, 2021 | MRK Merck & Co., Inc. | Frazier Kenneth C | Executive Chair | Sell | 663,881 | $82.26 | $54,611,361.66 | -35.6% | -5.3% | +27.1% | |
| Nov 8, 2021 | UTHR United Therapeutics Corp | Patusky Christopher50 | Director | Sell | 2,300 | $200.16 | $460,368.00 | -57.8% | -1.1% | +30.1% | |
| Nov 8, 2021 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairman &CEO | Sell | 3,083 | $200.94 | $619,498.02 | -96.0% | -1.1% | +30.1% | |
| Nov 8, 2021 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 220,362 | $6.25 | $1,377,985.53 | -4.2% | -32.7% | -53.7% | |
| Nov 5, 2021 | ZTS Zoetis Inc. | Norden Gregory | Director | Sell | 4,500 | $216.07 | $972,315.00 | -53.6% | -7.1% | -37.9% | |
| Nov 4, 2021 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $201.19 | $1,207,153.00 | -5.1% | +0.3% | +31.4% | |
| Nov 4, 2021 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 1,000,001 | $20.85 | $20,850,019.00 | -45.5% | +1.5% | -6.6% | |
| Nov 4, 2021 | MRK Merck & Co., Inc. | Deluca Richard R.45 | EVP&Pres, Merck Animal Heallth | Sell | 29,782 | $90.40 | $2,692,298.76 | -20.3% | -8.6% | +13.4% | |
| Nov 4, 2021 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairman &CEO | Sell | 3,083 | $200.00 | $616,600.00 | -96.0% | +0.3% | +31.4% | |
| Nov 4, 2021 | MRK Merck & Co., Inc. | Litchfield Caroline | EVP &CFO | Sell | 18,335 | $91.00 | $1,668,503.34 | -43.2% | -8.6% | +13.4% | |
| Nov 4, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 195,000 | $268.82 | $52,419,318.09 | - | -7.1% | +33.7% | |
| Nov 4, 2021 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 202,200 | $6.49 | $1,312,500.75 | -3.5% | -43.1% | -60.9% | |
| Nov 3, 2021 | MRK Merck & Co., Inc. | Karachun Rita A | Sr. VP Fince-global Controller | Sell | 25,000 | $88.45 | $2,211,215.00 | -41.1% | -6.7% | +15.3% | |
| Nov 2, 2021 | CPIX Cumberland Pharmaceuticals Inc | Galante Joseph C47 | Director | Buy | 284 | $2.65 | $752.60 | +0.3% | +24.9% | -5.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.